In Vivo Evaluation of Mimosa Pudica Linn. In the Management of Polycystic Ovary Using Rat Model.
Loading...
Date
2013-01
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
This study aimed to evaluate the effect of Mimosa pudica Linn. (MP) in the treatment of polycystic
ovary syndrome (PCOS) using a Letrozole induced PCOS rat model. PCOS was induced in albino wistar female rats
by daily oral administration of Letrozole for 21 days. The low (250 mg/kg), mid (500 mg/kg) and high dose (1000
mg/kg) of MP was given orally to the PCOS induced rats for 15 days post Letrozole induction to determine the
effective dose of MP in the treatment of PCOS. The biomarkers of ovarian function, plasma testosterone, estrogen
and progesterone were analyzed to determine the fluctuations in sex steroid levels in PCOS induced rats. The plasma
testosterone levels were found to be increased significantly in rats with PCOS whereas plasma estrogen and
progesterone levels were significantly decreased. When compared with control, the PCOS induced rats showed
characteristic ovary with high incidence of ovarian cysts with a diminished granulosa layer, significant number of
atretic follicles and absence of corpora lutea. All the end points assessed were significantly improved after the
treatment with mid and high dose of MP and achieved levels close to normal levels. The mid dose (500 mg/kg) and
high dose (1000 mg/kg) of MP were found to be effective in the treatment of PCOS induced by Letrozole in rats.
This effect of MP significantly reduced histopathological changes in ovary and endocrinological and biochemical
changes induced by hyperandrogenism. Thus MP was found to have a good potential to be a very good alternative
therapy in the treatment of PCOS.
Description
Keywords
Mimosa pudica Linn.., Letrozole, Polycystic ovary syndrome, Clomiphene citrate
Citation
Jadhav Mamata, Menon Sasikumar, Shailajan Sunita. In Vivo Evaluation of Mimosa Pudica Linn. In the Management of Polycystic Ovary Using Rat Model. International Journal of Applied Biology and Pharmaceutical Technology. 2013 Jan-Mar; 4(1): 285-292.